ID   PKR2_HUMAN              Reviewed;         384 AA.
AC   Q8NFJ6; A5JUU1; Q2M3C0; Q5TDY1; Q9NTT0;
DT   19-JUL-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2002, sequence version 1.
DT   07-APR-2021, entry version 161.
DE   RecName: Full=Prokineticin receptor 2;
DE            Short=PK-R2;
DE   AltName: Full=G-protein coupled receptor 73-like 1;
DE   AltName: Full=G-protein coupled receptor I5E;
DE   AltName: Full=GPR73b;
DE   AltName: Full=GPRg2;
GN   Name=PROKR2; Synonyms=GPR73L1, PKR2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=11886876; DOI=10.1074/jbc.m202139200;
RA   Lin D.C.-H., Bullock C.M., Ehlert F.J., Chen J.-L., Tian H., Zhou Q.-Y.;
RT   "Identification and molecular characterization of two closely related G
RT   protein-coupled receptors activated by prokineticins/endocrine gland
RT   vascular endothelial growth factor.";
RL   J. Biol. Chem. 277:19276-19280(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=12427552; DOI=10.1016/s0167-4781(02)00546-8;
RA   Soga T., Matsumoto S., Oda T., Saito T., Hiyama H., Takasaki J.,
RA   Kamohara M., Ohishi T., Matsushime H., Furuichi K.;
RT   "Molecular cloning and characterization of prokineticin receptors.";
RL   Biochim. Biophys. Acta 1579:173-179(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT MET-331.
RC   TISSUE=Testis;
RA   Martin A.L., Kaighin V.A., Aronstam R.S.;
RL   Submitted (APR-2007) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D.,
RA   Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G.,
RA   Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E.,
RA   Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D.,
RA   Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M.,
RA   Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D.,
RA   Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M.,
RA   Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A.,
RA   Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L.,
RA   Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L.,
RA   Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   SUBUNIT.
RX   PubMed=21161321; DOI=10.1007/s00018-010-0601-6;
RA   Marsango S., Bonaccorsi di Patti M.C., Barra D., Miele R.;
RT   "Evidence that prokineticin receptor 2 exists as a dimer in vivo.";
RL   Cell. Mol. Life Sci. 68:2919-2929(2011).
RN   [7]
RP   VARIANTS HH3 CYS-85; HIS-85; GLN-164; ARG-173; SER-178; ARG-210; CYS-268;
RP   SER-290; ILE-323 AND MET-331, AND VARIANT MET-335.
RX   PubMed=17054399; DOI=10.1371/journal.pgen.0020175;
RA   Dode C., Teixeira L., Levilliers J., Fouveaut C., Bouchard P.,
RA   Kottler M.-L., Lespinasse J., Lienhardt-Roussie A., Mathieu M., Moerman A.,
RA   Morgan G., Murat A., Toublanc J.-E., Wolczynski S., Delpech M., Petit C.,
RA   Young J., Hardelin J.-P.;
RT   "Kallmann syndrome: mutations in the genes encoding prokineticin-2 and
RT   prokineticin receptor-2.";
RL   PLoS Genet. 2:1648-1652(2006).
RN   [8]
RP   VARIANTS HH3 CYS-85; HIS-113; MET-115; GLN-164; ARG-173; SER-178; LEU-188;
RP   GLN-248; MET-331 AND TRP-357, AND CHARACTERIZATION OF VARIANTS HH3 CYS-85;
RP   HIS-113; MET-115; GLN-164; ARG-173; SER-178; LEU-188; GLN-248; MET-331 AND
RP   TRP-357.
RX   PubMed=18559922; DOI=10.1210/jc.2007-2654;
RA   Cole L.W., Sidis Y., Zhang C., Quinton R., Plummer L., Pignatelli D.,
RA   Hughes V.A., Dwyer A.A., Raivio T., Hayes F.J., Seminara S.B., Huot C.,
RA   Alos N., Speiser P., Takeshita A., Van Vliet G., Pearce S.,
RA   Crowley W.F. Jr., Zhou Q.Y., Pitteloud N.;
RT   "Mutations in prokineticin 2 and prokineticin receptor 2 genes in human
RT   gonadotrophin-releasing hormone deficiency: molecular genetics and clinical
RT   spectrum.";
RL   J. Clin. Endocrinol. Metab. 93:3551-3559(2008).
RN   [9]
RP   CHARACTERIZATION OF VARIANTS HH3 CYS-85; HIS-85; GLN-164; ARG-173; SER-178;
RP   ARG-210; CYS-268; SER-290; ILE-323 AND MET-331, AND SUBCELLULAR LOCATION.
RX   PubMed=18826963; DOI=10.1093/hmg/ddn318;
RA   Monnier C., Dode C., Fabre L., Teixeira L., Labesse G., Pin J.P.,
RA   Hardelin J.P., Rondard P.;
RT   "PROKR2 missense mutations associated with Kallmann syndrome impair
RT   receptor signalling activity.";
RL   Hum. Mol. Genet. 18:75-81(2009).
RN   [10]
RP   VARIANT HH3 CYS-268.
RX   PubMed=22927827; DOI=10.1371/journal.pgen.1002896;
RA   Hanchate N.K., Giacobini P., Lhuillier P., Parkash J., Espy C.,
RA   Fouveaut C., Leroy C., Baron S., Campagne C., Vanacker C., Collier F.,
RA   Cruaud C., Meyer V., Garcia-Pinero A., Dewailly D., Cortet-Rudelli C.,
RA   Gersak K., Metz C., Chabrier G., Pugeat M., Young J., Hardelin J.P.,
RA   Prevot V., Dode C.;
RT   "SEMA3A, a gene involved in axonal pathfinding, is mutated in patients with
RT   Kallmann syndrome.";
RL   PLoS Genet. 8:E1002896-E1002896(2012).
RN   [11]
RP   VARIANTS HH3 MET-115 AND GLY-202.
RX   PubMed=23643382; DOI=10.1016/j.ajhg.2013.04.008;
RA   Miraoui H., Dwyer A.A., Sykiotis G.P., Plummer L., Chung W., Feng B.,
RA   Beenken A., Clarke J., Pers T.H., Dworzynski P., Keefe K., Niedziela M.,
RA   Raivio T., Crowley W.F. Jr., Seminara S.B., Quinton R., Hughes V.A.,
RA   Kumanov P., Young J., Yialamas M.A., Hall J.E., Van Vliet G.,
RA   Chanoine J.P., Rubenstein J., Mohammadi M., Tsai P.S., Sidis Y., Lage K.,
RA   Pitteloud N.;
RT   "Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in
RT   individuals with congenital hypogonadotropic hypogonadism.";
RL   Am. J. Hum. Genet. 92:725-743(2013).
RN   [12]
RP   VARIANTS HH3 CYS-85; HIS-85; ILE-158; ARG-173; SER-290 AND MET-334.
RX   PubMed=25077900; DOI=10.1210/jc.2014-2110;
RA   Marcos S., Sarfati J., Leroy C., Fouveaut C., Parent P., Metz C.,
RA   Wolczynski S., Gerard M., Bieth E., Kurtz F., Verier-Mine O., Perrin L.,
RA   Archambeaud F., Cabrol S., Rodien P., Hove H., Prescott T., Lacombe D.,
RA   Christin-Maitre S., Touraine P., Hieronimus S., Dewailly D., Young J.,
RA   Pugeat M., Hardelin J.P., Dode C.;
RT   "The prevalence of CHD7 missense versus truncating mutations is higher in
RT   patients with Kallmann syndrome than in typical CHARGE patients.";
RL   J. Clin. Endocrinol. Metab. 99:E2138-2143(2014).
RN   [13]
RP   VARIANT HH3 HIS-113.
RX   PubMed=28858133; DOI=10.1097/md.0000000000007974;
RA   Ha J.H., Lee S., Kim Y., Moon J.I., Seo J., Jang J.H., Cho E.H., Kim J.M.,
RA   Rhee B.D., Ko K.S., Yoo S.J., Won J.C.;
RT   "Kallmann syndrome with a Tyr113His PROKR2 mutation.";
RL   Medicine (Baltimore) 96:E7974-E7974(2017).
CC   -!- FUNCTION: Receptor for prokineticin 2. Exclusively coupled to the G(q)
CC       subclass of heteromeric G proteins. Activation leads to mobilization of
CC       calcium, stimulation of phosphoinositide turnover and activation of
CC       p44/p42 mitogen-activated protein kinase.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:21161321}.
CC   -!- INTERACTION:
CC       Q8NFJ6; Q15848: ADIPOQ; NbExp=3; IntAct=EBI-12902928, EBI-10827839;
CC       Q8NFJ6; Q8TBE3: FNDC9; NbExp=3; IntAct=EBI-12902928, EBI-12142257;
CC       Q8NFJ6; P48165: GJA8; NbExp=3; IntAct=EBI-12902928, EBI-17458373;
CC       Q8NFJ6; P24593: IGFBP5; NbExp=3; IntAct=EBI-12902928, EBI-720480;
CC       Q8NFJ6; Q9Y385: UBE2J1; NbExp=3; IntAct=EBI-12902928, EBI-988826;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:18826963};
CC       Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Expressed in the ileocecum, thyroid gland,
CC       pituitary gland, salivary gland, adrenal gland, testis, ovary and
CC       brain.
CC   -!- DISEASE: Hypogonadotropic hypogonadism 3 with or without anosmia (HH3)
CC       [MIM:244200]: A disorder characterized by absent or incomplete sexual
CC       maturation by the age of 18 years, in conjunction with low levels of
CC       circulating gonadotropins and testosterone and no other abnormalities
CC       of the hypothalamic-pituitary axis. In some cases, it is associated
CC       with non-reproductive phenotypes, such as anosmia, cleft palate, and
CC       sensorineural hearing loss. Anosmia or hyposmia is related to the
CC       absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism
CC       is due to deficiency in gonadotropin-releasing hormone and probably
CC       results from a failure of embryonic migration of gonadotropin-releasing
CC       hormone-synthesizing neurons. In the presence of anosmia, idiopathic
CC       hypogonadotropic hypogonadism is referred to as Kallmann syndrome,
CC       whereas in the presence of a normal sense of smell, it has been termed
CC       normosmic idiopathic hypogonadotropic hypogonadism (nIHH).
CC       {ECO:0000269|PubMed:17054399, ECO:0000269|PubMed:18559922,
CC       ECO:0000269|PubMed:18826963, ECO:0000269|PubMed:22927827,
CC       ECO:0000269|PubMed:23643382, ECO:0000269|PubMed:25077900}. Note=The
CC       disease is caused by variants affecting distinct genetic loci,
CC       including the gene represented in this entry. The genetics of
CC       hypogonadotropic hypogonadism involves various modes of transmission.
CC       Oligogenic inheritance has been reported in some patients carrying
CC       mutations in PROKR2 as well as in other HH-associated genes including
CC       KAL1, SEMA3A, PROK2, GNRH1 and FGFR1 (PubMed:17054399, PubMed:22927827,
CC       PubMed:23643382). {ECO:0000269|PubMed:17054399,
CC       ECO:0000269|PubMed:22927827, ECO:0000269|PubMed:23643382,
CC       ECO:0000269|PubMed:28858133}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF506288; AAM48128.1; -; mRNA.
DR   EMBL; AB084081; BAC24022.1; -; mRNA.
DR   EMBL; EF577398; ABQ52418.1; -; mRNA.
DR   EMBL; AL121755; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC104959; AAI04960.1; -; mRNA.
DR   EMBL; BC104961; AAI04962.1; -; mRNA.
DR   CCDS; CCDS13089.1; -.
DR   RefSeq; NP_658986.1; NM_144773.3.
DR   RefSeq; XP_016883135.1; XM_017027646.1.
DR   SMR; Q8NFJ6; -.
DR   BioGRID; 126143; 6.
DR   IntAct; Q8NFJ6; 5.
DR   STRING; 9606.ENSP00000217270; -.
DR   BindingDB; Q8NFJ6; -.
DR   ChEMBL; CHEMBL5548; -.
DR   GuidetoPHARMACOLOGY; 336; -.
DR   GlyGen; Q8NFJ6; 2 sites.
DR   iPTMnet; Q8NFJ6; -.
DR   PhosphoSitePlus; Q8NFJ6; -.
DR   BioMuta; PROKR2; -.
DR   DMDM; 33112425; -.
DR   PaxDb; Q8NFJ6; -.
DR   PRIDE; Q8NFJ6; -.
DR   ProteomicsDB; 73317; -.
DR   Antibodypedia; 8176; 241 antibodies.
DR   DNASU; 128674; -.
DR   Ensembl; ENST00000217270; ENSP00000217270; ENSG00000101292.
DR   Ensembl; ENST00000678254; ENSP00000504128; ENSG00000101292.
DR   GeneID; 128674; -.
DR   KEGG; hsa:128674; -.
DR   UCSC; uc010zqw.3; human.
DR   CTD; 128674; -.
DR   DisGeNET; 128674; -.
DR   GeneCards; PROKR2; -.
DR   GeneReviews; PROKR2; -.
DR   HGNC; HGNC:15836; PROKR2.
DR   HPA; ENSG00000101292; Tissue enhanced (bone marrow, brain).
DR   MalaCards; PROKR2; -.
DR   MIM; 244200; phenotype.
DR   MIM; 607123; gene.
DR   neXtProt; NX_Q8NFJ6; -.
DR   OpenTargets; ENSG00000101292; -.
DR   Orphanet; 478; Kallmann syndrome.
DR   Orphanet; 432; Normosmic congenital hypogonadotropic hypogonadism.
DR   Orphanet; 95496; Pituitary stalk interruption syndrome.
DR   Orphanet; 3157; Septo-optic dysplasia spectrum.
DR   PharmGKB; PA30014; -.
DR   VEuPathDB; HostDB:ENSG00000101292.7; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT00940000154544; -.
DR   HOGENOM; CLU_009579_6_0_1; -.
DR   InParanoid; Q8NFJ6; -.
DR   OMA; QMYYKSY; -.
DR   OrthoDB; 664455at2759; -.
DR   PhylomeDB; Q8NFJ6; -.
DR   TreeFam; TF315303; -.
DR   PathwayCommons; Q8NFJ6; -.
DR   Reactome; R-HSA-375276; Peptide ligand-binding receptors.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   SIGNOR; Q8NFJ6; -.
DR   BioGRID-ORCS; 128674; 10 hits in 984 CRISPR screens.
DR   GeneWiki; Prokineticin_receptor_2; -.
DR   GenomeRNAi; 128674; -.
DR   Pharos; Q8NFJ6; Tchem.
DR   PRO; PR:Q8NFJ6; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   RNAct; Q8NFJ6; protein.
DR   Bgee; ENSG00000101292; Expressed in cortical plate and 36 other tissues.
DR   Genevisible; Q8NFJ6; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0004983; F:neuropeptide Y receptor activity; IEA:InterPro.
DR   GO; GO:0007623; P:circadian rhythm; IBA:GO_Central.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR000611; NPY_rcpt.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01012; NRPEPTIDEYR.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Disease variant; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Hypogonadotropic hypogonadism; Kallmann syndrome; Membrane;
KW   Receptor; Reference proteome; Transducer; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..384
FT                   /note="Prokineticin receptor 2"
FT                   /id="PRO_0000070083"
FT   TOPO_DOM        1..54
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        55..75
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        76..89
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        90..110
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        111..136
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        137..157
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        158..171
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        172..192
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        193..223
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        224..244
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        245..273
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        274..294
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        295..313
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        314..334
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        335..384
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        7
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        27
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        128..208
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VARIANT         85
FT                   /note="R -> C (in HH3; phenotype consistent with normosmic
FT                   idiopathic hypogonadotropic hypogonadism; decreased
FT                   signaling activity; dbSNP:rs141090506)"
FT                   /evidence="ECO:0000269|PubMed:17054399,
FT                   ECO:0000269|PubMed:18559922, ECO:0000269|PubMed:18826963,
FT                   ECO:0000269|PubMed:25077900"
FT                   /id="VAR_030957"
FT   VARIANT         85
FT                   /note="R -> H (in HH3; decreased signaling activity;
FT                   dbSNP:rs74315418)"
FT                   /evidence="ECO:0000269|PubMed:17054399,
FT                   ECO:0000269|PubMed:18826963, ECO:0000269|PubMed:25077900"
FT                   /id="VAR_030958"
FT   VARIANT         113
FT                   /note="Y -> H (in HH3; dbSNP:rs202203360)"
FT                   /evidence="ECO:0000269|PubMed:18559922,
FT                   ECO:0000269|PubMed:28858133"
FT                   /id="VAR_072173"
FT   VARIANT         115
FT                   /note="V -> M (in HH3; phenotype consistent with Kallmann
FT                   syndrome; dbSNP:rs138672528)"
FT                   /evidence="ECO:0000269|PubMed:18559922,
FT                   ECO:0000269|PubMed:23643382"
FT                   /id="VAR_069964"
FT   VARIANT         158
FT                   /note="V -> I (in HH3; phenotype consistent with Kallmann
FT                   syndrome; dbSNP:rs368732206)"
FT                   /evidence="ECO:0000269|PubMed:25077900"
FT                   /id="VAR_072978"
FT   VARIANT         164
FT                   /note="R -> Q (in HH3; phenotype consistent with Kallmann
FT                   syndrome; decreased signaling activity; dbSNP:rs751875578)"
FT                   /evidence="ECO:0000269|PubMed:17054399,
FT                   ECO:0000269|PubMed:18559922, ECO:0000269|PubMed:18826963"
FT                   /id="VAR_030959"
FT   VARIANT         173
FT                   /note="L -> R (in HH3; phenotype consistent with Kallmann
FT                   syndrome; decreased signaling activity; dbSNP:rs74315416)"
FT                   /evidence="ECO:0000269|PubMed:17054399,
FT                   ECO:0000269|PubMed:18559922, ECO:0000269|PubMed:18826963,
FT                   ECO:0000269|PubMed:25077900"
FT                   /id="VAR_030960"
FT   VARIANT         178
FT                   /note="W -> S (in HH3; decreased signaling activity;
FT                   dbSNP:rs201835496)"
FT                   /evidence="ECO:0000269|PubMed:17054399,
FT                   ECO:0000269|PubMed:18559922, ECO:0000269|PubMed:18826963"
FT                   /id="VAR_030961"
FT   VARIANT         188
FT                   /note="S -> L (in HH3; dbSNP:rs376239580)"
FT                   /evidence="ECO:0000269|PubMed:18559922"
FT                   /id="VAR_072174"
FT   VARIANT         202
FT                   /note="S -> G (in HH3; triallelic inheritance; the patient
FT                   also carries mutations in GNRH1 and FGFR1;
FT                   dbSNP:rs200755554)"
FT                   /evidence="ECO:0000269|PubMed:23643382"
FT                   /id="VAR_069965"
FT   VARIANT         210
FT                   /note="Q -> R (in HH3; phenotype consistent with Kallmann
FT                   syndrome; decreased signaling activity; abolished ligand
FT                   binding; dbSNP:rs74315417)"
FT                   /evidence="ECO:0000269|PubMed:17054399,
FT                   ECO:0000269|PubMed:18826963"
FT                   /id="VAR_030962"
FT   VARIANT         248
FT                   /note="R -> Q (in HH3; dbSNP:rs376142095)"
FT                   /evidence="ECO:0000269|PubMed:18559922"
FT                   /id="VAR_072175"
FT   VARIANT         268
FT                   /note="R -> C (in HH3; benign variant; signaling activity
FT                   is impaired; dbSNP:rs78861628)"
FT                   /evidence="ECO:0000269|PubMed:17054399,
FT                   ECO:0000269|PubMed:18826963, ECO:0000269|PubMed:22927827"
FT                   /id="VAR_030963"
FT   VARIANT         290
FT                   /note="P -> S (in HH3; phenotype consistent with Kallmann
FT                   syndrome; signaling activity is impaired; impaired cell
FT                   surface-targeting; dbSNP:rs149992595)"
FT                   /evidence="ECO:0000269|PubMed:17054399,
FT                   ECO:0000269|PubMed:18826963, ECO:0000269|PubMed:25077900"
FT                   /id="VAR_030964"
FT   VARIANT         323
FT                   /note="M -> I (in HH3; phenotype consistent with Kallmann
FT                   syndrome; signaling activity is impaired;
FT                   dbSNP:rs74315419)"
FT                   /evidence="ECO:0000269|PubMed:17054399,
FT                   ECO:0000269|PubMed:18826963"
FT                   /id="VAR_030965"
FT   VARIANT         331
FT                   /note="V -> M (in HH3; likely benign variant;
FT                   dbSNP:rs117106081)"
FT                   /evidence="ECO:0000269|PubMed:17054399,
FT                   ECO:0000269|PubMed:18559922, ECO:0000269|PubMed:18826963,
FT                   ECO:0000269|Ref.3"
FT                   /id="VAR_030966"
FT   VARIANT         334
FT                   /note="V -> M (in HH3; phenotype consistent with Kallmann
FT                   syndrome; dbSNP:rs371564610)"
FT                   /evidence="ECO:0000269|PubMed:25077900"
FT                   /id="VAR_072979"
FT   VARIANT         335
FT                   /note="T -> M (in dbSNP:rs755562438)"
FT                   /evidence="ECO:0000269|PubMed:17054399"
FT                   /id="VAR_030967"
FT   VARIANT         357
FT                   /note="R -> W (in HH3; dbSNP:rs375036628)"
FT                   /evidence="ECO:0000269|PubMed:18559922"
FT                   /id="VAR_072176"
SQ   SEQUENCE   384 AA;  43996 MW;  2D5BFA3655347B5E CRC64;
     MAAQNGNTSF TPNFNPPQDH ASSLSFNFSY GDYDLPMDED EDMTKTRTFF AAKIVIGIAL
     AGIMLVCGIG NFVFIAALTR YKKLRNLTNL LIANLAISDF LVAIICCPFE MDYYVVRQLS
     WEHGHVLCAS VNYLRTVSLY VSTNALLAIA IDRYLAIVHP LKPRMNYQTA SFLIALVWMV
     SILIAIPSAY FATETVLFIV KSQEKIFCGQ IWPVDQQLYY KSYFLFIFGV EFVGPVVTMT
     LCYARISREL WFKAVPGFQT EQIRKRLRCR RKTVLVLMCI LTAYVLCWAP FYGFTIVRDF
     FPTVFVKEKH YLTAFYVVEC IAMSNSMINT VCFVTVKNNT MKYFKKMMLL HWRPSQRGSK
     SSADLDLRTN GVPTTEEVDC IRLK
//
